These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


228 related items for PubMed ID: 3105142

  • 21. Treatment with OKT3 and cyclosporine for acute allograft rejection.
    Schulak JA, Mayes JT, Hricik DE.
    Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
    Chatenoud L.
    Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatments.
    Goldstein G, Norman DJ, Shield CF, Kreis H, Burdick J, Flye MW, Rivolta E, Starzl T, Monaco A.
    Prog Clin Biol Res; 1986 Oct; 224():239-49. PubMed ID: 3540993
    [No Abstract] [Full Text] [Related]

  • 31. Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection.
    Gilbert EM, Eiswirth CC, Renlund DG, Menlove RL, DeWitt CW, Freedman LA, Herrick CM, Gay WA, Bristow MR.
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):45-53. PubMed ID: 3105140
    [No Abstract] [Full Text] [Related]

  • 32. Single center randomized trial using ATG v OKT3 treatment in steroid resistant rejection crises after kidney transplantation.
    Blümke M, Kirste G, Wanner U, Wilms H.
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1747. PubMed ID: 2652571
    [No Abstract] [Full Text] [Related]

  • 33. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation.
    Steininger R, Mühlbacher F, Hamilton G, Längle F, Gnant M, Popow T, Sautner T, Götzinger P, Wamser P, Stockenhuber F.
    Transplant Proc; 1991 Aug; 23(4):2269-71. PubMed ID: 1908154
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Orthoclone OKT3 (Muromonab CD3)--the indications for and manner of its use. Side effects and their prevention].
    Filev A, Kumanov Kh, Slavov Ch, Tsvetkov M.
    Khirurgiia (Sofiia); 1989 Aug; 42(6):80-2. PubMed ID: 2517512
    [Abstract] [Full Text] [Related]

  • 38. Detection of cytomegalovirus infection under therapy with OKT3 monoclonal antibodies.
    Müller T, Tolle S, Keuchel M, Schindler S, Hocke G, Steinmetz A, Beck J, Lange H.
    Transplant Proc; 1990 Aug; 22(4):1807-8. PubMed ID: 2167534
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. OKT3 immunoprophylaxis in human liver transplantation.
    Mühlbacher F, Steininger R, Längle F, Sautner T, Gnant M, Götzinger P, Piza F, Popow T.
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2253-4. PubMed ID: 2652731
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 12.